🔎 Trials Near Me

Hem › Osteosarkom › Massachusetts

Kliniska studier för Osteosarkom i Massachusetts

9 studier för Osteosarkom söker deltagare vid platser i Massachusetts.

Städer i Massachusetts

Officiell studietext (engelska)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • Dana-Farber Cancer Institute, Boston
RekryterarFas 2
Ålder 12 till 39 · Alla kön · Uppdaterad 29 sep. 2026 · NCT04616560

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
RekryterarFas 3
Upp till ålder 50 · Alla kön · Uppdaterad 25 aug. 2026 · NCT05235165

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Dana-Farber Cancer Institute, Boston
RekryterarFas 1/2
12 Months – 30 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT04851119

SPEARHEAD-3 Pediatric Study

  • Dana Farber Cancer Institute, Boston
RekryterarFas 1/2
Ålder 2 till 21 · Alla kön · Uppdaterad 11 aug. 2026 · NCT05642455

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • Dana Farber Cancer Institute, Boston
RekryterarFas 1/2
Upp till ålder 30 · Alla kön · Uppdaterad 3 aug. 2026 · NCT06239272

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Dana-Farber Cancer Institute, Boston
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 18 maj 2026 · NCT01790152

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

  • Dana Farber Cancer Institute, Boston
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 1 maj 2026 · NCT07357519

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

  • Dana-Farber Cancer Institute, Boston
RekryterarFas 2
Ålder 12 och äldre · Alla kön · Uppdaterad 17 apr. 2026 · NCT05019703

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
RekryterarFas 1/2
Ålder 12 till 49 · Alla kön · Uppdaterad 19 feb. 2026 · NCT06709495

Från ClinicalTrials.gov, data hämtad 2 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.